Overview
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies
Eligibility
Inclusion Criteria:
- Signed inform consent
- Histolgically verified solid tumour
- Receiving systemic therapy for neoplasm
- Has archival tumour tissue
- Provide biosamples with living tumour tissue or blood samples for immunologic assessment
Exclusion Criteria:
- Concurrent Lymphoprolipherative disorder
- Patients after stem cell or bone marrow thansplantation
- Incomplete informaton on previous cancer history or medical history
- Patients with known primary immunodeficiency
- Patients receiving immunosupressive therapy for concurrent illness
- Pregnant patients